American Century Companies Inc. lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 33.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,983,702 shares of the medical equipment provider’s stock after selling 3,512,787 shares during the period. American Century Companies Inc. owned 0.51% of Boston Scientific worth $173,126,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in BSX. GSA Capital Partners LLP grew its position in Boston Scientific by 21.9% in the 2nd quarter. GSA Capital Partners LLP now owns 12,513 shares of the medical equipment provider’s stock valued at $347,000 after buying an additional 2,247 shares in the last quarter. AHL Partners LLP lifted its holdings in Boston Scientific by 65.2% in the 2nd quarter. AHL Partners LLP now owns 99,959 shares of the medical equipment provider’s stock valued at $2,771,000 after acquiring an additional 39,455 shares during the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in Boston Scientific by 0.7% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 236,479 shares of the medical equipment provider’s stock valued at $6,554,000 after acquiring an additional 1,650 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Boston Scientific by 57.7% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 48,338 shares of the medical equipment provider’s stock valued at $1,340,000 after acquiring an additional 17,683 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in Boston Scientific by 2.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 44,496 shares of the medical equipment provider’s stock valued at $1,233,000 after acquiring an additional 1,178 shares during the last quarter. Hedge funds and other institutional investors own 89.84% of the company’s stock.
A number of research firms have commented on BSX. Barclays reaffirmed a “buy” rating and set a $32.00 price objective on shares of Boston Scientific in a research note on Wednesday, January 10th. BMO Capital Markets reaffirmed a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a research note on Wednesday, November 29th. Needham & Company LLC raised shares of Boston Scientific from a “buy” rating to a “strong-buy” rating and upped their price objective for the company from $25.04 to $32.00 in a research note on Friday, December 8th. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 29th. Finally, Canaccord Genuity dropped their target price on Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific presently has an average rating of “Buy” and a consensus target price of $31.00.
Shares of Boston Scientific Corporation (NYSE:BSX) opened at $26.81 on Thursday. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. The firm has a market capitalization of $35,854.15, a P/E ratio of 383.00, a PEG ratio of 1.89 and a beta of 0.81.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, meeting the consensus estimate of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same period in the prior year, the business earned $0.30 earnings per share. Boston Scientific’s revenue for the quarter was up 9.9% compared to the same quarter last year. sell-side analysts anticipate that Boston Scientific Corporation will post 1.37 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://weekherald.com/2018/02/15/boston-scientific-corporation-bsx-shares-sold-by-american-century-companies-inc.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.